Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-22T23:18:06.914Z Has data issue: false hasContentIssue false

Monocyte count in schizophrenia and related disorders: a systematic review and meta-analysis

Published online by Cambridge University Press:  17 March 2020

Mario Gennaro Mazza*
Affiliation:
Department of Medicine and Surgery, University of Milano Bicocca, Monza, MB, Italy
Martina Capellazzi
Affiliation:
Department of Medicine and Surgery, University of Milano Bicocca, Monza, MB, Italy
Sara Lucchi
Affiliation:
Department of Medicine and Surgery, University of Milano Bicocca, Monza, MB, Italy
Ilaria Tagliabue
Affiliation:
Department of Medicine and Surgery, University of Milano Bicocca, Monza, MB, Italy
Aurora Rossetti
Affiliation:
Department of Medicine and Surgery, University of Milano Bicocca, Monza, MB, Italy
Massimo Clerici
Affiliation:
Department of Medicine and Surgery, University of Milano Bicocca, Monza, MB, Italy
*
Author for correspondence: Mario Gennaro Mazza, Email: [email protected]

Abstract

Objective:

Increasing evidence suggests that immunological and inflammatory dysfunctions may play an important role in predisposition, onset, and progression of schizophrenia and related psychosis. The activation of cells of the mononuclear phagocyte system, especially microglia and monocytes, has been reported in schizophrenia. We carried out this systematic review and meta-analysis to investigate if there are significant differences in monocyte count comparing healthy controls with people suffering from schizophrenia and related disorders.

Methods:

We searched main electronic databases; nine records met all our criteria and were included in the meta-analysis. Meta-analyses based on random effects models have been carried out generating pooled standardised mean differences (SMDs) of monocyte count in peripheral blood between schizophrenia and related psychosis and healthy controls. Heterogeneity was estimated. Relevant sensitivity and subgroup analyses were conducted.

Results:

Patients showed higher monocyte count as compared with healthy control (SMD = 0.393; p = 0.001). Heterogeneity across studies was from moderate to high (I2 = 65.952%); sensitivity analysis leaving out two studies responsible for most of the heterogeneity showed a slightly higher SMD. Subgroup analyses confirmed this result, showing no significant differences in the effect size across different study characteristics.

Conclusions:

Monocyte count can be considered an indirect marker of microglia activation in the central nervous system. Thus, the observed higher monocyte count in patients could be considered as a possible peripheral marker of microgliaʼs activation in schizophrenia disorder.

Type
Review Article
Copyright
© Scandinavian College of Neuropsychopharmacology 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Begg, CB and Mazumdar, M 1994. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 10881101.CrossRefGoogle Scholar
Bergink, V, Gibney, SM and Drexhage, HA 2014. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biological Psychiatry 75, 324331.CrossRefGoogle ScholarPubMed
Beumer, W, Gibney, SM, Drexhage, RC, Pont-Lezica, L, Doorduin, J, Klein, HC, Steiner, J, Connor, TJ, Harkin, A, Versnel, MA and Drexhage, HA 2012. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. Journal of Leukocyte Biology 92, 959975.CrossRefGoogle ScholarPubMed
Cai, HQ, Catts, VS, Webster, MJ, Galletly, C, Liu, D, O'Donnell, M, Weickert, TW and Weickert, CS 2018. Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation. Molecular Psychiatry 25, 761775.CrossRefGoogle ScholarPubMed
Dasdemir, S, Kucukali, CI, Bireller, ES, Tuzun, E and Cakmakoglu, B 2016. Chemokine gene variants in schizophrenia. Nordic Journal of Psychiatry 70, 407412.CrossRefGoogle Scholar
de Picker, LJ, Morrens, M, Chance, SA and Boche, D 2017. Microglia and brain plasticity in acute psychosis and schizophrenia illness course: a meta-review. Frontiers in Psychiatry 8, 238.CrossRefGoogle ScholarPubMed
Dimitrov, DH 2011. Correlation or coincidence between monocytosis and worsening of psychotic symptoms in veterans with schizophrenia? Schizophrenia Research 126, 306307.Google ScholarPubMed
Drexhage, RC, Hoogenboezem, TA, Cohen, D, Versnel, MA, Nolen, WA, van Beveren, NJ and Drexhage, HA 2011. An activated set point of t-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. The International Journal of Neuropsychopharmacology 14, 746755.CrossRefGoogle ScholarPubMed
Drexhage, RC, van der Heul-Nieuwenhuijsen, L, Padmos, RC, van Beveren, N, Cohen, D, Versnel, MA, Nolen, WA and Drexhage, HA 2010. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. a study in naturalistically treated patients. The International Journal of Neuropsychopharmacology 13, 13691381.CrossRefGoogle ScholarPubMed
Eaton, WW, Byrne, M, Ewald, H, Mors, O, Chen, CY, Agerbo, E and Mortensen, PB 2006. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. The American Journal of Psychiatry 163, 521528.CrossRefGoogle ScholarPubMed
Frydecka, D, Krzystek-Korpacka, M, Lubeiro, A, Stramecki, F, Stańczykiewicz, B, Beszłej, JA, Piotrowski, P, Kotowicz, K, Szewczuk-Bogusławska, M, Pawlak-Adamska, E and Misiak, B 2018. Profiling inflammatory signatures of schizophrenia: a cross-sectional and meta-analysis study. Brain, Behavior, and Immunity 71, 2836.CrossRefGoogle ScholarPubMed
Gallego, JA, Blanco, EA, Husain-Krautter, S, Madeline Fagen, E, Moreno-Merino, P, Del Ojo-Jiménez, JA, Ahmed, A, Rothstein, TL, Lencz, T and Malhotra, AK 2018. Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: new data and an updated meta-analysis. Schizophrenia Research 202, 6471.CrossRefGoogle Scholar
Garcia-Rizo, C, Casanovas, M, Fernandez-Egea, E, Oliveira, C, Meseguer, A, Cabrera, B, Mezquida, G, Bioque, M, Kirkpatrick, B and Bernardo, M 2017. Blood cell count in antipsychotic-naive patients with non-affective psychosis. Early Intervention in Psychiatry 13, 95100.CrossRefGoogle ScholarPubMed
Guo, J, Liu, C, Wang, Y, Feng, B and Zhang, X 2015. Role of T helper lymphokines in the immune-inflammatory pathophysiology of schizophrenia: systematic review and meta-analysis. Nordic Journal of Psychiatry 69, 364372.CrossRefGoogle Scholar
Gurung, J, Chamlagai, D, Bera, NK, Chaudhuri, TK and Singh, B 2018. Elevated levels of C-reactive protein and IL-6 among the antipsychotic medicating schizophrenia patients of Siliguri, West Bengal, India. Nordic Journal of Psychiatry 72, 311317.CrossRefGoogle ScholarPubMed
Haraldsson, HM, Ettinger, U and Sigurdsson, E 2011. Developments in schizophrenia genetics: from linkage to microchips, deletions and duplications. Nordic Journal of Psychiatry 65, 8288.CrossRefGoogle ScholarPubMed
Higgins, J and Green, S 2008. Cochrane Handbook For Systematic Reviews Of Interventions. Oxford: Wiley-Blackwell.CrossRefGoogle Scholar
Higgins, JPT, Thompson, SG, Deeks, JJ and Altman, DG 2003. Measuring inconsistency in meta-analyses. BMJ (Clinical Research ed.) 327, 557560.CrossRefGoogle ScholarPubMed
Kahn, RS and Sommer, IE 2015. The neurobiology and treatment of first-episode schizophrenia. Molecular Psychiatry 20, 8497.CrossRefGoogle ScholarPubMed
Kéri, S, Szabó, C and Kelemen, O 2017. Antipsychotics influence Toll-like receptor (TLR) expression and its relationship with cognitive functions in schizophrenia. Brain, Behavior, and Immunity 62, 256264.CrossRefGoogle Scholar
Kessler, RC, Birnbaum, H, Demler, O, Falloon, IR, Gagnon, E, Guyer, M, Howes, MJ, Kendler, KS, Shi, L, Walters, E and Wu, EQ 2005. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biological Psychiatry 58, 668676.CrossRefGoogle Scholar
Khandaker, GM and Dantzer, R 2016. Is there a role for immune-to-brain communication in schizophrenia? Psychopharmacology 233, 15591573.CrossRefGoogle Scholar
Khandaker, GM, Zammit, S, Burgess, S, Lewis, G and Jones, PB 2018. Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort. Brain, Behavior, and Immunity 69, 264272.CrossRefGoogle Scholar
Klemettilä, JP, Kampman, O, Seppälä, N, Viikki, M, Hämäläinen, M, Moilanen, E and Leinonen, E 2017. Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine. Nordic Journal of Psychiatry 71, 8995.CrossRefGoogle ScholarPubMed
Larsen, JB, Iversen, VC and Reitan, SK 2018. Association of psychosis, affective disorders and diseases affecting the immune system. Nordic Journal of Psychiatry 72, 145149.CrossRefGoogle ScholarPubMed
Laskaris, LE, Di Biase, MA, Everall, I, Chana, G, Christopoulos, A, Skafidas, E, Cropley, VL and Pantelis, C 2016. Microglial activation and progressive brain changes in schizophrenia. British Journal of Pharmacology 173, 666680.CrossRefGoogle Scholar
Mazza, MG, Lucchi, S, Rossetti, A and Clerici, M 2019. Neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio and platelet-lymphocyte ratio in non-affective psychosis: a meta-analysis and systematic review. The World Journal of Biological Psychiatry the Official Journal of the World Federation of Societies of Biological Psychiatry, 137.Google ScholarPubMed
Miller, BJ, Buckley, P, Seabolt, W, Mellor, A and Kirkpatrick, B 2011. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 70, 663671.CrossRefGoogle ScholarPubMed
Miller, BJ, Culpepper, N and Rapaport, MH 2014. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clinical Schizophrenia & Related Psychoses 7, 223230.CrossRefGoogle ScholarPubMed
Miller, BJ and Goldsmith, DR 2017. Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future directions. Neuropsychopharmacology Official Publication of the American College of Neuropsychopharmacology 42, 299317.CrossRefGoogle ScholarPubMed
Miller, BJ, Kandhal, P, Rapaport, MH, Mellor, A and Buckley, P 2015. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses. Brain, Behavior, and Immunity 45, 2835.CrossRefGoogle ScholarPubMed
Moody, G and Miller, BJ 2018. Total and differential white blood cell counts and hemodynamic parameters in first-episode psychosis. Psychiatry Research 260, 307312.CrossRefGoogle ScholarPubMed
Müller, N, Wagner, JK, Krause, D, Weidinger, E, Wildenauer, A, Obermeier, M, Dehning, S, Gruber, R and Schwarz, MJ 2012. Impaired monocyte activation in schizophrenia. Psychiatry Research 198, 341346.CrossRefGoogle Scholar
Nikkilä, HV, Müller, K, Ahokas, A, Miettinen, K, Rimón, R and Andersson, LC 1999. Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. The American Journal of Psychiatry 156, 17251729.Google ScholarPubMed
Notter, T and Meyer, U 2017. Microglia and schizophrenia: where next? Molecular Psychiatry 22, 788789.CrossRefGoogle ScholarPubMed
Orhan, F, Schwieler, L, Fatouros-Bergman, H, Malmqvist, A, Cervenka, S, Collste, K, Flyckt, L, Farde, L, Sellgren, CM, Piehl, F, Karolinska Schizophrenia Project (KaSP) Consortium, Engberg, G and Erhardt, S 2018. Increased number of monocytes and plasma levels of MCP-1 and YKL-40 in first-episode psychosis. Acta Psychiatrica Scandinavica 138, 432440.CrossRefGoogle ScholarPubMed
Özdin, S, Sarisoy, G and Böke, Ö 2017. A comparison of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratios in schizophrenia and bipolar disorder patients - a retrospective file review. Nordic Journal of Psychiatry 71, 509512.CrossRefGoogle ScholarPubMed
Paez, A 2017. Grey literature: an important resource in systematic reviews. Journal of Evidence-based Medicine.CrossRefGoogle ScholarPubMed
Patsopoulos, NA, Evangelou, E and Ioannidis, JPA 2008. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. International Journal of Epidemiology 37, 11481157.CrossRefGoogle ScholarPubMed
Pavlović, M, Babić, D, Rastović, P, Babić, R and Vasilj, M 2016. Metabolic syndrome, total and differential white blood cell counts in patients with schizophrenia. Psychiatria Danubina 28 Suppl 2, 216222.Google ScholarPubMed
Plavén-Sigray, P, Matheson, GJ, Collste, K, Ashok, AH, Coughlin, JM, Howes, OD, Mizrahi, R, Pomper, MG, Rusjan, P, Veronese, M, Wang, Y and Cervenka, S 2018. Positron emission tomography studies of the glial cell marker translocator protein in patients with psychosis: a meta-analysis using individual participant data. Biological Psychiatry 84, 433442.CrossRefGoogle ScholarPubMed
Prinz, M and Priller, J 2014. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nature Reviews. Neuroscience 15, 300312.CrossRefGoogle ScholarPubMed
Radewicz, K, Garey, LJ, Gentleman, SM and Reynolds, R 2000. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. Journal of Neuropathology and Experimental Neurology 59, 137150.CrossRefGoogle ScholarPubMed
Sacks, HS, Reitman, D, Pagano, D and Kupelnick, B 1996. Meta-analysis: an update. The Mount Sinai Journal of Medicine, New York 63, 216224.Google ScholarPubMed
Stang, A 2010. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology 25, 603605.CrossRefGoogle ScholarPubMed
Sterne, JA, Egger, M and Smith, GD 2001. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ (Clinical Research ed.) 323, 101105.CrossRefGoogle ScholarPubMed
Tomasik, J, Rahmoune, H, Guest, PC and Bahn, S 2016. Neuroimmune biomarkers in schizophrenia. Schizophrenia Research 176, 313.CrossRefGoogle Scholar
Trépanier, MO, Hopperton, KE, Mizrahi, R, Mechawar, N and Bazinet, RP 2016. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Molecular Psychiatry 21, 10091026.CrossRefGoogle ScholarPubMed
Turhan, L, Batmaz, S, Kocbiyik, S and Soygur, AH 2016. The role of tumour necrosis factor alpha and soluble tumour necrosis factor alpha receptors in the symptomatology of schizophrenia. Nordic Journal of Psychiatry 70, 342350.CrossRefGoogle ScholarPubMed
van Kesteren, CF, Gremmels, H, de Witte, LD, Hol, EM, Van Gool, AR, Falkai, PG, Kahn, RS, Sommer, IE 2017. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. Translational Psychiatry 7, e1075.CrossRefGoogle ScholarPubMed
Wilke, I, Arolt, V, Rothermundt, M, Weitzsch, C, Hornberg, M and Kirchner, H 1996. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience 246, 279284.Google ScholarPubMed
Yang, Y, Wan, C, Li, H, Zhu, H, La, Y, Xi, Z, Chen, Y, Jiang, L, Feng, G and He, L 2006. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Analytical Chemistry 78, 35713576.Google ScholarPubMed
Yüksel, RN, Ertek, i.e., Dikmen, AU and Göka, E 2018. High neutrophil-lymphocyte ratio in schizophrenia independent of infectious and metabolic parameters. Nordic Journal of Psychiatry 72, 336340.CrossRefGoogle ScholarPubMed
Zorrilla, EP, Cannon, TD, Gur, RE and Kessler, J 1996. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease? Biological Psychiatry 40, 825833.CrossRefGoogle ScholarPubMed
Supplementary material: Image

Mazza et al. supplementary material

Figure S1

Download Mazza et al. supplementary material(Image)
Image 40.8 KB